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Background: Artemisinin-based combination therapy (ACT) is the recommended first-line treatment of falciparum
malaria in all endemic countries. Artemisinin resistance in Plasmodium falciparum has been confirmed in the Greater
Mekong subregion (GMS). Dihydroartemisinin-piperaquine (DAPQ) is the most commonly used ACT in China. To
understand the DAPQ sensitivity of P. falciparum, DAPQ resistance was monitored in vivo along the China-Myanmar
border from 2007 to 2013.
Methods: Eligible patients with mono-infections of P. falciparum were recruited to this study after obtaining full informed
consent. DAPQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients
were followed up for 42 days. Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and
recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier
method. Treatment outcome was assessed according to the WHO recommended standards.
Results: 243 patients were completed valid follow-up. The fever clearance time (FCT) and asexual parasite clearance
times (APCT) were, respectively, 36.5 ± 10.9 and 43.5 ± 11.8 hours, and there was an increasing trend of both FCT
(F = 268.41, P < 0.0001) and APCT (F = 88.6, P < 0.0001) from 2007 to 2013. Eight (3.3%, 95% confidence interval,
1.4–6.4%) patients present parasitaemia on day three after medication; however they were spontaneous cure on
day four. 241 (99.2%; 95% CI, 97.1–99.9%) of the patients were adequate clinical and parasitological response
(ACPR) and the proportions of ACPR had not changed significantly from 2007 to 2013 (X2 = 2.81, P = 0.7288).
Conclusion: In terms of efficacy, DAPQ is still an effective treatment for falciparum malaria. DAPQ sensitivity in
P. falciparum had not significantly changed along the China-Myanmar border of Yunnan Province, China. However
more attentions should be given to becoming slower fever and parasite clearance.
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Malaria remains one of the major global public health
problems [1]. Intensive efforts in controlling malaria are
producing impressive results. The number of malaria
cases has fallen by more than half in 40% of malaria en-
demic countries in the recent decade. Estimates suggest
that nearly 750,000 lives have been saved in Africa alone
thanks to malaria control measures [2]. Artemisinin-
based combination therapy is the recommended first-
line treatment of falciparum malaria in all endemic
countries. However, the emergence of artemisinin resist-
ance in malaria parasites is threatening malaria control
and elimination programmes. Artemisinin resistance in
Plasmodium falciparum has been identified and con-
firmed in Cambodia, Thailand, Myanmar, and Vietnam
[2-10]. Other suspected foci have been identified in the
Greater Mekong Subregion (GMS), but are not yet con-
firmed. The threat must be taken seriously. Resistance to
previous generations of anti-malarials spread rapidly
around the world, resulting in an increase in child mor-
tality and untold number of deaths [2]. The artemisinin-
based combination therapy (ACT) is the most potent
weapon in treating falciparum malaria [11] and no other
anti-malarial is available that offers the same level of effi-
cacy and tolerability. In order to contain artemisinin re-
sistance, the World Health Organization (WHO) Global
Malaria Programme launched the Global Plan for Arte-
misinin Resistance Containment. Surveillance of artemi-
sinin sensitivity in P. falciparum is one of important
components to prevent the emergence of new foci of re-
sistance, as well as to limit the spread of resistance [2].
China has declared a national policy for malaria elim-
ination by 2020 [12,13]. ACT is the first-line therapy for
falciparum malaria and dihydroartemisinin-piperaquine
(DAPQ) is the most common anti-malarial drug in
China [14]. Historically, population movement has con-
tributed to the spread of disease. Failure to consider this
factor contributed to failure in malaria eradication cam-
paigns in the 1950s and 1960s [15,16]. Resistance to
anti-malarial drugs has often threatened malaria elimin-
ation efforts and historically has led to the short-term
resurgence of malaria incidences and deaths [17]. With
the development of modern transportation, the world is
becoming smaller and smaller. China has the largest
population in the world and Chinese people move around
globally [18], especially to some parts of the GMS where
artemisinin resistance has been identified and confirmed.
The Yunnan Province is in southwestern China and be-
longs to the GMS. The Chinese Myanmar border is one of
the very few remaining areas of malaria transmission in all
of China. In 2013, only 423 malaria cases, 81 (19.1%)
P. falciparum, were reported along the border in China,
and the annual parasite incidence was only 0.9 (95% CI,
0.8–1.0) per ten thousand. Monitoring artemisinin resistancein Yunnan Province would contribute both to malaria
elimination in China and in containing global artemisinin
resistance. From 2007 to 2013, DAPQ resistance was mon-
itored in vivo to determine the dynamics of P. falciparum
sensitivity to DAPQ on the China- Myanmar border.
Methods
Surveillance sites and time
China and Myanmar share 2,185 kilometre border.
There are 19 counties of China and fives special regions
of Myanmar on the border. Populations includes 4,687,
896 residents of 19 counties of Yunnan Province of
China and 586,000 residents of the five Special Regions
of Myanmar. Due to the complex emergency situation in
the five Special Regions of Myanmar, where fell outside
the coverage of national malaria control efforts sup-
ported by Myanmar’s Ministry of Health, effective access
of malaria interventions could only be achieved from
China. In March, 2008, the baseline survey of evaluation
indicator for the sixth grant to China of the Global Fund
to fight AIDS, Tuberculosis and Malaria showed that the
parasite prevalence rate was 13.6% (761/5585, 95% CI:
12.7–14.6%), and the proportion of P. falciparum among
slides with parasites was 38.1% (290/761, 95% CI: 34.6–
41.7%) in the five Special Regions of Myanmar. In elim-
inating settings, malaria predominantly occurs in border
areas and imported cases tend to represent a majority of
recorded cases [19]. In order to recruit malaria patients
for the study, surveillance was conducted in Yingjiang of
Dehong Prefecture in 2007, Menglian of Puer Prefecture
in 2009, in both Tengchong of Baoshan Prefecture and
Yingjiang of Dehong Prefecture from 2010 to 2013
(Figure 1).
Patients and recruiting criteria
Patients whose axillary temperature was ≥ 37.5°C or with
a history of fever during the previous 24 hours were di-
agnosed by using microscopy of thick and thin blood
smears. Patients with mono-infections of P. falciparum
were recruited to this study, after obtaining full in-
formed consent. Only patients older than one year, body
weight ≥ 5 kg, presenting with parasite density 500–
100,000 parasites per μl were enrolled into the study.
Imported malaria was identified as patients who had
travelled from endemic areas of Myanmar within one
month and were diagnosed as malaria in China [13].
Patients were excluded from the study if any of the fol-
lowing criteria were present: (1) positive pregnancy
test or breastfeeding; (2) complicated malaria; (3) hav-
ing taken any anti-malarial, tetracycline and sulphona-
mides derivatives drugs within the past seven days; (4)
history of hypersensitivity to any of the study drugs;
(5) presence of febrile conditions due to diseases other
than malaria (e.g. measles, acute lower respiratory tract
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Figure 1 Surveillance sites: Menglian, Tengchong and Yingjian in Yunnan Province of China and relative to neighbouring countries.
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known underlying chronic or severe diseases (e.g. car-
diac, renal and hepatic diseases, HIV/AIDS); (6) over
60 years; (7) presence of severe malnutrition (defined
as a child whose growth standard is below –3 z-score,
has symmetrical oedema involving at least the feet or
has a mid-upper arm circumference < 110 mm); and,
(8) unable to follow-up [20,21].
Drug and administration
DAPQ was manufactured by Zhejiang Holley Nanhu
Pharmaceutical Co. Ltd, and provided by the West Pacific
Office of WHO (WPRO/WHO). The drug quality was
controlled by WPRO/WHO too. The batch numbers of
DAPQ were 600807 (manufactured on 30 Aug 2007),
460909 (23 Sep 2009) and 400911 (20 Sep 2011). Each
tablet contains 40 mg base dihydroartemisinin and
320 mg piperaquine phosphate. DAPQ was given once
a day for three days and the dosing were based on the
recommendation of WPRO/WHO. For convenient ad-
ministration, the doses were calculated into tablets for dif-
ferent categories of kg body weight ranges (Table 1). The
treatment intake was observed while the patients visited
the hospital as requested for the first three days. Patientsof late clinical failure and late parasitological failure
were subsequently given a total dose of artemisinin-
naphthoquine 24.5 mg/kg (naphthoquine 7 mg/kg and
artemisinin 17.5 mg/kg), once a day for three days [22].
Laboratory and in vivo clinical monitoring
Parasite microscopy was conducted and axillary tempera-
tures were measured on admission and every 8–12 hours
in the first three days. Patients were asked to visit the hos-
pital and further parasitological examinations were per-
formed on day 7, 14, 21, 28, 35 and 42. In a case of patient
had not visited the hospital, a researcher actively visited
the patient home to prepare blood smears. Malaria blood
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by two independent microscopists and considered nega-
tive if no parasites were seen after examination of 200 oil-
immersion fields in a thick blood film. Parasite clearance
was defined as no asexual parasite per 500 white blood
cells being detected in two continuously microscopic ex-
aminations with an 8–12 hr interval. Fever clearance was
defined as axillary temperatures <37.1°C in duration of
24 hours. Parasites were counted per 500 white blood
cells. The number of parasites was calculated as per μl of
blood by the level of 8,000 of leukocyte per μl [23]. A filter
paper dried blood spot (about 100ul blood) was prepared
on admission, day 7, 14, 21, 28, 35 and 42, day of treat-
ment failure or at any other unscheduled visit, and subse-
quently stored in plastic zip bags containing silica gel
dessicant. Polymerase chain reaction (PCR) was per-
formed respectively to distinguish between reinfection and
recurrence of asexual parasites of blood stages, to confirm
the Plasmodium species or to detect mixed infection.
DNA extraction and genotype analysis were conducted
based on investigation of the three polymorphic genetic
markers msp1, msp2, and glurp, according to WHO rec-
ommended procedures [24]. Recrudescence was defined
as at least one identical allele for each of the three markers
in the pre-treatment and post-treatment samples. New in-
fections were diagnosed when all alleles for at least one of
the markers differed between the two samples. Cases with
new infection were excluded from the analysis [25]. In
case of failure after day 7, patients whose PCR results were
unknown were excluded from the analysis too [11].
Classification standards for treatment outcome
Treatment outcome was categorized based on the WHO
definitions for early treatment failure (ETF), late clinical
failure (LCF), late parasitological failure (LPF), and ad-
equate clinical and parasitological response (ACPR). The
ETF definition was to conform to any one of the criteria:
(1) danger signs or severe malaria on day 1, 2 or 3, in
the presence of parasitaemia; (2) parasitaemia on day 2
higher than on day 0, irrespective of axillary temperature;
(3) parasitaemia on day 3 with axillary temperature ≥ 37.5°C;
and, (4) parasitaemia on day 3 ≥ 25% of count on day 0. The
LCF definition was to satisfy any one of the criteria: (1) dan-
ger signs or severe malaria in the presence of parasitaemia
on any day between day 4 and day 42 in patients who did
not previously meet any of the criteria of ETF; and, (2) pres-
ence of parasitaemia on any day between day 4 and day 42
with axillary temperature ≥ 37.5°C in patients who did not
previously meet any of the criteria of ETF. LPF definition is
to satisfy presence of parasitaemia on any day between day 7
and day 42 with axillary temperature < 37.5°C in patients
who did not previously meet any criteria of ETF or LCF.
ACPR definition was to satisfy absence of parasitaemia on
day 42, irrespective of axillary temperature, in patientswho did not previously meet any criteria of ETF, LCF
or LPF [20,21].
Statistical analysis and resistance assessment
The data were by double independent data entry and
analysed by the Kaplan-Meier method [22,26]. The pa-
tients of loss to follow-up and withdrawal from the study
were not involved into the analysis. Mean fever and
parasite clearance time were compared by covariance
through Epi Info 6.04 [22,26]. The proportions of ETF,
LCF, LPF and ACPR were, respectively, compared by
Chi-square test for trend of quantitative data [27]. The
treatment outcome was assessed on the basis of parasite
clearance from the blood.
Ethical approval
According to the Helsinki Declaration, ethical approval
for the study was granted by the Ethics Committee of
Yunnan Institute of Parasitic Diseases, China. The pur-
pose of the study was explained and then approval was
sought from patients and their caretakers. Informed
written consent was obtained from patient or carers of
Child patients. All results were kept confidential and
were unlinked to any identifying information.
Results
A total of 290 falciparum malaria patients were recruited
in the study during 2007–2013 (the study was inter-
rupted in 2008 because of shortage of funding), 22(7.6%)
withdrew, 25(8.6%) were lost at follow-up, and 243
(83.8%) completed valid follow-up, of which 178 (72.3%)
were Burmese (Table 2). The fever clearance time (FCT)
and asexual parasite clearance times (APCT) were, re-
spectively, 36.5 ± 10.9 and 43.5 ± 11.8 hours. The results
of covariance analysis showed an increasing trend of
both FCT (F = 268.41, P < 0.0001) and APCT (F = 88.6,
P < 0.0001) (Table 3). Eight (3.3%, 95% confidence inter-
val, 1.4–6.4%) patients present parasitaemia on day 3
after medication, three in 2010, one in 2011, three in
2012 and one in 2013 (Figure 2); and then parasites were
spontaneously cleared by day 4. The results showed that
241 (99.2%; 95% CI, 97.1–99.9%) of the patients were
ACPR, one ETF in 2012 and one LCF in 2007, without
LPF (Table 3). The results of Chi-square test for trend of
quantitative data showed that percentages of ACPR had
not changed significantly from 2007 to 2013 (X2 = 2.81,
P = 0.7288) (Table 3). The ETF patient was cured spon-
taneously by day four. The LCF patients responded well
to the three-day treatment regimen of artemisinin-
naphthoquine tablets. The ETF and LCF cases were
imported from the neighbouring districts of Myanmar.
The PCR identified the LCF as recrudescence on day
28 in 2007, and did not identify any new infection of
P. falciparum.
Table 2 Baseline characteristics of falciparum malaria patients on the China-Myanmar border, Yunnan Province, China
2007 (n = 38) 2009 (n = 71) 2010 (n = 27) 2011 (n = 17) 2012 (n = 63) 2013 (n = 27) Total (n = 243)
Sex
Male (%) 19 (50) 32 (45.1) 21 (77.8) 17 (100) 44 (69.8) 20 (74.1) 153 (63.0)
Female (%) 19 (50) 39 (54.9) 6 (22.2) 0 19 (30.2) 7 (25.9) 90 (37.0)
Nationality
Chinese (%) 1(2.6) 10 (14.1) 3 (11.1) 17 (100) 21 (33.3) 13 (48.1) 65 (26.7)
Burmese (%) 37 (97.4) 61 (85.9) 24 (88.9) 0 42 (66.7) 14 (51.9) 178 (72.3)
Age (years)
Mean (± SD) 16.3 (9.2) 25.0 (3.8) 26.3 (4.2) 33.6 (1.2) 26.1 (8.3) 28.0 (9.6) 25.9 (6.8)
Range 2–60 7–56 2–49 19–48 4–60 2–56 2–60
Body temperature (°C)
Mean (± SD) 38.3 (0.7) 38.5 (0.6) 38.3 (0.5) 39.3 (0.3) 38.8 (0.9) 38.7 (0.8) 38.6 (0.7)
Rang 37–40.5 37.2–39.4 36.8–40.4 38.0–40.0 36.1–40.4 37.8–39.7 36.1–39.7
Parasite count (per ul)
Geometric mean 11100 11257 73784 38776 24257 24886 30678
Range (per μl) 760–37120 500–45200 540–821700 5129–119657 596–167132 524–162960 596–821700
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Plasmodium falciparum resistance to artemisinin deriva-
tives in Southeast Asia threatens malaria control and
elimination activities worldwide [28,29]. The results of
the study showed that the FCT and APCT were increas-
ing from 2007 to 2013 (Table 3); 3.3% patients present
parasitaemia on day 3 after medication, but were spon-
taneously cured by day 4 without treatment. The princi-
pal pharmacodynamic advantage of using artemisinins is
that they accelerate parasite clearance by clearing young,
circulating, ring-stage parasites and preventing the furtherTable 3 Treatment responses of falciparum malaria patients on t







Mean (± SD) 24.5 (8.1) 34.8 (10.4) 36.4 (9.9) 35.3 (9.5)
Range 16–40 20–48 20–72 22–96
50% APCT (hr)
Mean (± SD) 24.2 (7.8) 24.6 (8.7) 25.8 (7.4) 26.8 (8.5)
Range 3–29 7–25 8–48 8–48
APCT (hr)
Mean (± SD) 38.4 (7.5) 39.8 (7.9) 41.8 (8.4) 40.9 (9.2)
Range 19–46 16–72 19–72 18–96
ETF (%, 95%CI) 0 (0, 0–9.3) 0 (0, 0–7.0) 0 (0, 0–12.8) 0 (0, 0–19.
LCF (%, 95%CI) 1 (2.6, 0.1–13.8) 0 (0, 0–5.1) 0 (0, 0–12.8) 0 (0, 0–19.
LPF (%, 95%CI) 0 (0, 0–9.3) 0 (0, 0–5.1) 0 (0, 0–12.8) 0 (0, 0–19.








Note: FCT = fever clearance times (hours), APCT = asexual parasite clearance times (hours);
ACPR= adequate clinical and parasitological response, and 95%CI = 95% confidence intervmaturation and sequestration of these parasites. This ef-
fect accounts for the rapidity of the therapeutic response,
its lifesaving benefit in patients with severe malaria,
and the notable gametocytocidal activity of the drugs
[3,28-30]. The reduced susceptibility of ring-stage par-
asites causes the slow parasite clearance [29-33]. The
markedly prolonged time to parasite clearance showed
a decline in the efficacy of DAPQ during the six years.
However, DAPQ was still highly efficacious for the treat-
ment of falciparum malaria on the China-Myanmar border








43.3 (11.4) 45.7 (11.6) 36.5 (10.9) F = 268.4 <0.0001
24–96 23–96 16–96
25.9 (8.2) 26.3 (8.4) 25.2 (8.2) F = 4.14 0.0013
6–48 7–48 3–48
42.6 (11.3) 52.6 (12.3) 43.5 (11.8) F = 88.6 <0.0001
16–96 20–72 16–96
5) 1 (1.6, 0.04–8.5) 0 (0, 0–12.8) 1 (0.4, 0–2.3) X2 = 2.61 0.7591
5) 0 (0, 0–5.7) 0 (0, 0–12.8) 1 (0.4, 0–2.3) X2 = 5.00 0.4164







X2 = 2.81 0.7288
ETF= early treatment failure, LCF = late clinical failure, LPF = late parasitological failure,
al.
Figure 2 Number (%) of patients of parasitaemia presence on day 1, 2 and 3 after medication.
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portions of ACPR had not changed significantly from 2007
to 2013 (X2 = 2.81, P = 0.7288).
DAPQ sensitivity of P. falciparum had been monitored
on the China-Myanmar border. Sun et al. reported that
DAPQ was efficacious for falciparum malaria treatment
in 2006 [34], however Liu et al. reported a 97.0% of cu-
mulative success rate (CSR) and reduced DAPQ sensitiv-
ity in P. falciparum of a trial in which the only eight
tablets of DAPQ (a dosage for >40 kg body weight) were
used for uncomplicated falciparum malaria treatment
[35]. In the study by Liu et al., the technical limitation
was to not use PCR to distinguish between re-infection
and recrudescence, and they conduct their study in Wa
State of Myanmar, where P falciparum prevalence was
high during 2007–2008. The technical limitation and the
different regimen might result in the declined CSR, and
geographic differences might be one of explanations for
reported differences too. Huang et al. reported a 95.9%
(47/49) of artesunate CSR and a high frequency of muta-
tions in pfcrt, pfdhfr and pfdhps associated with chloro-
quine and sulphadoxine–pyrimethamine resistance and
no pfatp6 mutation in P. falciparum [36]. Wang et al.
reported low levels of point mutations in pfmdr1 and
pfatp6 prevalence and no pfmdr1 gene amplification de-
tected [37]. The results of the two molecular epidemiology
studies showed lack of molecular basis of artemisinin re-
sistance along China-Myanmar border. All these investiga-
tions together were not enough to confirm the artemisinin
resistance in P. falciparum along the China-Myanmar
border.
Several limitations should be considered while using
the results of study. Firstly, both total and yearly sample
size were limited by the difficulty in recruiting patients
because of low malaria incidence in eliminating settings,only total 1011 falciparum malaria cases were reported
during 2010–2013. Secondly, the surveillance activity
was interrupted in 2008 because of shortage of funding.
Thirdly, the surveillance sites had to be changed in
order to recruit falciparum malaria patients, in Yingjiang
in 2007, Menglian in 2009, in both Tengchong and
Yingjiang from 2010 to 2013, however all the three
sites are on the China-Myanmar border. Fourthly, the
study did not use any pharmacokinetics (PK) measure-
ment to ascertain drug absorption and to characterize
the concentration–time profile of drugs and the rele-
vant covariates (e.g. immunity, young age and drug in-
teractions), so it did not exclude confounding effect of
some variables that could influence APCT [38]. Fifthly,
mutations of PF3D7_1343700 kelch propeller domain
(K13-propeller) are important determinants of artemisi-
nin resistance [29]; the study did not investigate mutant
K13-propeller alleles. According to the new working def-
inition of ACT or artesunate monotherapy resistance, the
suspected resistance is as evidenced by either ≥5% K13-
propeller domain mutants or ≥10% of patients who are
parasitaemic on day three; and the confirmed resistance
should satisfy both ≥5% K13-propeller domain mutants
and ≥10% of patients with parasitaemia on day three, or
by the persistence of parasites for seven days, or by the
presence of parasites on day three and recrudescence
within 28/42 days [29,39]. The monitored results showed
that only 3.3% (8/243) of patients presented parasitaemia
by day three and only 0.8% (2/243) were ETF or LCF. Ac-
cording to the new working definition DAPQ was still sen-
sitive in P. falciparum along the China-Myanmar border.
While artemisinin resistance was found on the western
border of Cambodia-Thailand and the western border of
Thailand-Myanmar [40], P. falciparum was still sensitive
to artemisinins on the China-Myanmar border. The
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fections are correlated with transmission intensity as well
as the spread of anti-malarial resistance. Despite the inten-
sified control efforts and the decline of malaria prevalence
along China-Myanmar border, the parasite population size
and transmission intensity remained high enough to allow
effective genetic recombination of the parasites and
continued maintenance of genetic diversity in China-
Myanmar border area [41]. Therefore, surveillance for
artemisinin resistance in P. falciparum should be main-
tained and containment activities should be further
strengthened to monitor the spread of resistance, de-
fine therapeutic and operational strategies to understand
its molecular basis and counter its impact [28,42]. In
terms of monitoring artemisinin resistance, treatment fail-
ure of ACT is more direct and accurate [43], so it may be
more useful in artemisinin sensitivity surveillance.
Detection of drug efficacy is only the first step to pro-
ducing accessible and useful information for decision
makers. The translation of increased access to data on
health outcomes into usable evidence for rational policy
and planning requires a global coordination and com-
munication effort [44]. In terms of containment measures,
a 97.5% of DAPQ CSR for P. falciparum treatment had
been reported in Hainan Province of China in 2004 [45]
and then 100% in 2008 [46], P. falciparum has been elimi-
nated by using the strategy of early diagnosis and treat-
ment (EDT) with ACT [47]. The emergence of resistance
to artesunate in P. falciparum, the strategy of EDT with
ACT has reduced malaria in the migrant population
living on the Thai-Myanmar border [48]. The addition
of one dose of primaquine to ACT could help to coun-
ter the spread of artemisinin resistance [49]. Despite
the 8-aminoquinoline compound cause patients with
G6PD deficiency haemolysis, it can sterilize gameto-
cytes of P. falciparum. Lower doses of the gametocyto-
cide would be safer, might still be very effective for
blocking transmission.
Conclusion
In terms of efficacy, DAPQ is still effective for falciparum
malaria treatment. DAPQ sensitivity in P. falciparum had
not significantly changed along the China-Myanmar
border of Yunnan Province, China. However more at-
tentions should be given to becoming slower fever and
parasite clearance, surveillance for artemisinin resist-
ance in P. falciparum should be maintained and con-
tainment measures are urgently needed.
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